------------------------------------------------------------
[link removed]


**
PrEP and more PrEP: An update and important resources
------------------------------------------------------------
February 7, 2022

Dear Advocate,

2022 is a critical year for the evolving role of PrEP, anti-retroviral drugs (ARVS) used to prevent HIV. Currently, two types of daily pills (FTC/TDF and F/TAF), injectable cabotegravir administered every two months (CAB-LA) and a monthly Dapivirine Vaginal Ring (DVR) are approved in some countries for at least some populations. But each face challenges that must be overcome for these proven interventions to effectively reach people who need and want them.

In addition, the pipeline of next-generation PrEP products in research and development is intensely dynamic. But if advocacy, global coordination, funding, and community-centered responses come together now, PrEP programs can be scaled, and these biomedical options can be translated into actual choices. This work is essential for the world to hit 2030 targets for ending the epidemic.

AVAC is tracking all things PrEP. Here are some resources to keep you up to date and to help frame key issues for your advocacy.

Global PrEP Tracker ([link removed])
Check out global trends in oral PrEP initiations with AVAC’s just updated PrEP Tracker ([link removed]) , found on PrEPWatch.org ([link removed]) . 2021 saw marked increases in global PrEP uptake, up 50 percent from 2020. Five countries in sub-Saharan Africa are driving this growth with expanding programs: Kenya, Nigeria, South Africa, Uganda and Zambia. Get details on the data ([link removed]) here ([link removed]) .

[link removed]
Overview of the Pipeline ([link removed]) [link removed]
These trends can be put into context with the Biomedical HIV Prevention ([link removed]) Research in 2022 and ([link removed]) Beyond ([link removed]) which provides a concise update on the full landscape of biomedical interventions, including: PrEP products in the market, next-gen products in the pipeline, including multipurpose products (MPTs) and vaccines and broadly neutralizing antibodies. And check our handy cheat-sheet on Evolving Designs for HIV Prevention Trials ([link removed]) .

[link removed]
Primer on Injectable Cabotegravir for PrEP ([link removed])
With the recent US FDA approval of CAB for PrEP, we’ve updated our advocates’ primer to outline what’s known and what’s next for this new prevention option.

Two Training Packages for Peer-led Product Introduction ([link removed])
The HIV Prevention Ambassador Training Package ([link removed]) for adolescent girlshttps://www.prepwatch.org/resource/ambassador-training-package/ and young women (AGYW) supports them to play a meaningful role in the rollout of PrEP products in their communities. Developed by the PROMISE & CHOICE consortiums, it includes a training manual on essential topics and session instructions, and a toolkit. This version of the Ambassador Training Package ([link removed]) is intended for all priority populations, including men who have sex with men, people who inject drugs, serodiscordant couples, pregnant and breastfeeding people, sex workers, transgender people as well as adolescent girls and young women.

[link removed] Strategy for the Future of PrEP, From Research to Rollout ([link removed])
The Biomedical Prevention Implementation Collaborative (BioPIC ([link removed]) ) is developing a model for a comprehensive and coordinated global platform for the introduction of new biomedical products for HIV prevention. The BioPIC Adaptable Framework ([link removed]) incorporates stakeholders from all stages of product development and delivery, from research to rollout. And watch this space for the upcoming launch of BioPIC’s online dashboard that will be tracking efforts to introduce

[link removed] Lessons from Oral PrEP – and Implications for the Future ([link removed])
AVAC’s six-year HIV Prevention Market Manager ([link removed]) program produced a ([link removed]) wealth of insights ([link removed]) on how to get rollout right ([link removed]) . Learning the lessons from oral PrEP in ([link removed]) troduction is essential ([link removed]) , and this series of issue briefs ([link removed]) distills the priorities for advocates, implementers, funders, product developers and ministries of health. And in case you missed it, check out the recent webinar recording ([link removed]) and summary
([link removed]) .

[link removed] to Support the Introduction of the Dapivirine Vaginal Ring ([link removed])
This package of resources supporting the introduction of the ([link removed]) Dapivirine Vaginal Ring ([link removed]) includes: advocacy messages, an introductory slide deck, FAQ’s and more.

Are We PrEPared This Time? ([link removed])
Just last week, the AIDS Foundation Chicago ([link removed]) , AVAC and partners hosted a webinar, Are we PrEPared this time? Ensuring a Swift Translation of Research into Community Impact, featuring presentations and debate on what must happen for positive research results to effectively reach communities without delay. A link to the recording is here ([link removed]) .

The PrEP field is moving at an historic pace, but significant obstacles threaten to derail the potential PrEP holds for contributing to the end of the epidemic by 2030. Our joint work will confront these challenges. Keep watching this space for the information, resources, analysis and convening opportunities to keep this work on track.

Best,
AVAC

============================================================

Forward This Issue Do you know someone who might be interested in receiving this newsletter?
** Forward > ([link removed])

Unsubscribe You're receiving this because you signed up for our newsletter. Not interested any longer?
** Unsubscribe > ([link removed])

Contact Us T: +1 212 796 6423
E: ** [email protected] (mailto:[email protected])
W: ** www.avac.org ([link removed])
** ([link removed])
** ([link removed])
** ([link removed])